82 FR 42624 - Schedules of Controlled Substances: Temporary Placement of FUB-AMB Into Schedule I
DEPARTMENT OF JUSTICE
Drug Enforcement Administration Federal Register Volume 82, Issue 174 (September 11, 2017)
Drug Enforcement Administration
Federal Register Volume 82, Issue 174 (September 11, 2017)
| Page Range | 42624-42627 | |
| FR Document | 2017-17639 |
[Federal Register Volume 82, Number 174 (Monday, September 11, 2017)] [Proposed Rules] [Pages 42624-42627] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-17639] [[Page 42624]] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration 21 CFR Part 1308 [Docket No. DEA-472] Schedules of Controlled Substances: Temporary Placement of FUB- AMB Into Schedule I AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Proposed amendment; notice of intent. ----------------------------------------------------------------------- SUMMARY: The Administrator of the Drug Enforcement Administration is issuing this notice of intent to publish a temporary order to schedule the synthetic cannabinoid, Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3- carboxamido)-3-methylbutanoate [FUB-AMB, MMB-FUBINACA, AMB-FUBINACA], into Schedule I. This action is based on a finding by the Administrator that the placement of this synthetic cannabinoid into Schedule I of the Controlled Substances Act is necessary to avoid an imminent hazard to the public safety. When it is issued, the temporary scheduling order will impose the administrative, civil, and criminal sanctions and regulatory controls applicable to Schedule I controlled substances under the Controlled Substances Act on the manufacture, distribution, possession, importation, exportation of, and research and conduct with, instructional activities of this synthetic cannabinoid. DATES: September 11, 2017. FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598- 6812. SUPPLEMENTARY INFORMATION: This notice of intent contained in this document is issued pursuant to the temporary schedule provisions of 21 U.S.C. 811(h). The Drug Enforcement Administration (DEA) intends to issue a temporary scheduling order (in the form of a temporary amendment) to add FUB-AMB to Schedule I under the Controlled Substances Act.\1\ The temporary scheduling order will be published in the Federal Register, but will not be issued before October 11, 2017. --------------------------------------------------------------------------- \1\ Though DEA has used the term ``final order'' with respect to temporary scheduling orders in the past, this notice of intent adheres to the statutory language of 21 U.S.C. 811(h), which refers to a ``temporary scheduling order.'' No substantive change is intended. --------------------------------------------------------------------------- Legal Authority Section 201 of the Controlled Substances Act (CSA), 21 U.S.C. 811, provides the Attorney General with the authority to temporarily place a substance into Schedule I of the CSA for two years without regard to the requirements of 21 U.S.C. 811(b) if he finds that such action is necessary to avoid an imminent hazard to the public safety. 21 U.S.C. 811(h)(1). In addition, if proceedings to control a substance are initiated under 21 U.S.C. 811(a)(1), the Attorney General may extend the temporary scheduling for up to one year. 21 U.S.C. 811(h)(2). Where the necessary findings are made, a substance may be temporarily scheduled if it is not listed in any other schedule under section 202 of the CSA, 21 U.S.C. 812, or if there is no exemption or approval in effect for the substance under section 505 of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. 355. 21 U.S.C. 811(h)(1); 21 CFR part 1308. The Attorney General has delegated scheduling authority under 21 U.S.C. 811 to the Administrator of the DEA. 28 CFR 0.100. Background Section 201(h)(4) of the CSA 21 U.S.C. 811(h)(4), requires the Administrator to notify the Secretary of the Department of Health and Human Services (HHS) of his intention to temporarily place a substance into Schedule I of the CSA.\2\ The Acting Administrator transmitted notice of his intent to place FUB-AMB in Schedule I on a temporary basis to the Assistant Secretary for Health by letter dated May 19, 2017. The Assistant Secretary responded to this notice of intent by letter dated June 9, 2017, and advised that based on a review by the Food and Drug Administration (FDA), there were no approved new drug applications or active investigational new drug applications for FUB- AMB. The Assistant Secretary also stated that the HHS has no objection to the temporary placement of FUB-AMB into Schedule I of the CSA. FUB- AMB is not currently listed in any schedule under the CSA, and no exemptions or approvals are in effect for FUB-AMB under section 505 of the FDCA, 21 U.S.C. 355. The DEA has found that the control of FUB-AMB in Schedule I on a temporary basis is necessary to avoid imminent hazard to the public safety. --------------------------------------------------------------------------- \2\ As discussed in a memorandum of understanding entered into by the Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIDA), the FDA acts as the lead agency within the HHS in carrying out the Secretary's scheduling responsibilities under the CSA, with the concurrence of NIDA. 50 FR 9518, Mar. 8, 1985. The Secretary of the HHS has delegated to the Assistant Secretary for Health of the HHS the authority to make domestic drug scheduling recommendations. 58 FR 35460, July 1, 1993. --------------------------------------------------------------------------- To find that placing a substance temporarily into Schedule I of the CSA is necessary to avoid an imminent hazard to the public safety, the Administrator is required to consider three of the eight factors set forth in 21 U.S.C. 811(c): The substance's history and current pattern of abuse; the scope, duration and significance of abuse; and what, if any, risk there is to the public health. 21 U.S.C. 811(h)(3). Consideration of these factors includes actual abuse, diversion from legitimate channels, and clandestine importation, manufacture, or distribution. 21 U.S.C. 811(h)(3). A substance meeting the statutory requirements for temporary scheduling may only be placed in Schedule I. 21 U.S.C. 811(h)(1). Substances in Schedule I are those that have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. 21 U.S.C. 812(b)(1). FUB-AMB The illicit use of the synthetic cannabinoid (SC) methyl 2-(1-(4- fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (Street names: FUB-AMB, MMB-FUBINACA, AMB-FUBINACA) has dramatically increased over the past 12 months posing an imminent threat to public safety. Available data and information for FUB-AMB, summarized below, indicates that this SC has a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. The DEA's three factor analysis is available in its entirety under ``Supporting and Related Material'' of the public docket for this action at www.regulations.gov under Docket Number DEA-372. Synthetic Cannabinoids SCs are substances synthesized in laboratories that mimic the biological effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient in marijuana. It is believed that SCs were first introduced on the designer drug market in several European countries as ``herbal incense'' before the initial encounter in the United States by U.S. Customs and Border Protection (CBP) in November 2008. From 2009 to the present, misuse and abuse of SCs has increased in the United States with law enforcement encounters describing [[Page 42625]] SCs applied onto plant material and in designer drug products intended for human consumption. It has been demonstrated that the substances and the associated designer drug products are abused for their psychoactive properties. With many generations of SCs having been encountered since 2009, FUB-AMB is one of the latest, and the abuse of these substances is negatively impacting communities. As observed by the DEA and CBP, SCs originate from foreign sources, such as China. Bulk powder substances are smuggled via common carrier into the United States and find their way to clandestine designer drug product manufacturing operations located in residential neighborhoods, garages, warehouses, and other similar destinations throughout the country. According to online discussion boards and law enforcement encounters, applying by spraying or mixing the SCs with plant material provides a vehicle for the most common route of administration--smoking (using a pipe, a water pipe, or rolling the drug-laced plant material in cigarette papers). FUB-AMB has no accepted medical use in the United States. Use of this specific SC has been reported (see factor 6) to result in adverse effects in humans. Use of other SCs has resulted in signs of addiction and withdrawal and based on the similar pharmacological profile of FUB- AMB, it is believed that there will be similar observed adverse effects. FUB-AMB is a SC that has pharmacological effects similar to the Schedule I hallucinogen THC and other temporarily and permanently controlled Schedule I synthetic cannabinoid substances. In addition, the misuse of FUB-AMB has been associated with multiple overdoses requiring emergency medical intervention (see factor 6). With no approved medical use and limited safety or toxicological information, FUB-AMB has emerged on the designer drug market, and the abuse of this substance for its psychoactive properties is concerning. Factor 4. History and Current Pattern of Abuse Synthetic cannabinoids have been developed by researchers over the last 30 years as tools for investigating the endocannabinoid system, (e.g. determining CB1 and CB2 receptor activity). The first encounter of SCs within the United States occurred in November 2008 by CBP. Since then, the popularity of SCs in general and their associated products has increased as evidenced by law enforcement seizures, public health information, and media reports. FUB-AMB was originally encountered in 2014, but has since seen a large increase in its illicit use. The misuse of FUB-AMB has been associated with multiple overdoses requiring emergency medical intervention. Research and clinical reports have demonstrated that SCs are applied onto plant material so that the material may be smoked as users attempt to obtain a euphoric and psychoactive ``high,'' believed to be similar to marijuana. Data gathered from a published study, and supplemented by discussions on Internet Web sites, demonstrate that these products are being abused mainly by smoking for their psychoactive properties. The adulterated products are marketed as ``legal'' alternatives to marijuana. In recent cases of overdoses, FUB- AMB has been encountered in the form of herbal products, similar to the SCs that have been previously available. The powder form of SCs is typically dissolved in solvents (e.g., acetone) before being applied to plant material or dissolved in a propellant intended for use in electronic cigarette devices. Law enforcement personnel have encountered various application methods including buckets or cement mixers in which plant material and one or more SCs are mixed together, as well as large areas where the plant material is spread out so that a dissolved SC mixture can be applied directly. Once mixed, the SC plant material is then allowed to dry before manufacturer's package the product for distribution, ignoring any control mechanisms to prevent contamination or to ensure a consistent, uniform concentration of the substance in each package. Adverse health consequences may also occur from directly ingesting the drug during the manufacturing process. FUB-AMB, similar to other SCs, has been encountered in the form of dried leave or herbal blends. The designer drug products laced with SCs, including FUB-AMB, are often sold under the guise of ``herbal incense'' or ``potpourri,'' use various product names, and are routinely labeled ``not for human consumption.'' Additionally, these products are marketed as a ``legal high'' or ``legal alternative to marijuana'' and are readily available over the Internet, in head shops, or sold in convenience stores. There is an incorrect assumption that these products are safe, that they are a synthetic form of marijuana, and that labeling these products as ``not for human consumption'' is a legal defense to criminal prosecution under the Controlled Substances Analogue Enforcement Act. It is believed most abusers of SCs or SC-related products are smoking the product following application to plant material. Law enforcement has also begun to encounter new variations of SCs in liquid form. It is believed abusers have been applying the liquid to hookahs or ``e-cigarettes,'' which allows the user to administer a vaporized liquid that can be inhaled. Factor 5. Scope, Duration and Significance of Abuse SCs including FUB-AMB continue to be encountered on the illicit market regardless of scheduling actions that attempt to safeguard the public from the adverse effects and safety issues associated with these substances. Novel substances are encountered each month, differing only by small modifications intended to avoid prosecution while maintaining the pharmacological effects. Law enforcement and health care professionals continue to report the abuse of these substances and their associated products. As described by the National Institute on Drug Abuse (NIDA), many substances being encountered in the illicit market, specifically SCs, have been available for years but have reentered the marketplace due to a renewed popularity. The threat of serious injury to the individual following the ingestion of FUB-AMB and other SCs persists. The following information details information obtained through NFLIS \3\ (queried on May 16, 2017), including dates of first encounter, exhibits/reports, and locations. --------------------------------------------------------------------------- \3\ The National Forensic Laboratory Information System (NFLIS) is a national drug forensic laboratory reporting system that systematically collects results from drug chemistry analyses conducted by state and local forensic laboratories in the United States. --------------------------------------------------------------------------- FUB-AMB: NFLIS--6,522 reports, first encountered in June 2014, locations include: Arkansas, Arizona, California, Colorado, Florida, Georgia, Iowa, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Maryland, Minnesota, Missouri, Mississippi, North Dakota, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Virginia, Wisconsin, and Wyoming. Factor 6. What, if Any, Risk There Is to the Public Health FUB-AMB has been identified in overdose cases attributed to its abuse. Adverse health effects reported from these incidents involving FUB-AMB have included: Nausea, persistent vomiting, agitation, altered mental [[Page 42626]] status, seizures, convulsions, loss of consciousness, and cardiotoxicity. By sharing pharmacological similarities with Schedule I substances ([Delta]9-THC, JWH-018 and other temporarily and permanently controlled schedule I SCs), SCs pose a risk to the abuser. While these adverse effects have been shown by a variety of SCs, similar concerns remain regarding the welfare of the user as it relates to abuse of products laced with FUB-AMB. The risk of adverse health effects is further increased by the fact that similar products vary in the composition and concentration of SCs applied on the plant material. Finding of Necessity of Schedule I Placement To Avoid Imminent Hazard to Public Safety In accordance with 21 U.S.C. 811(h)(3), based on the available data and information summarized above, the continued uncontrolled manufacture, distribution, importation, exportation, conduct of research and chemical analysis, possession, and abuse of FUB-AMB poses an imminent hazard to the public safety. The DEA is not aware of any currently accepted medical uses for FUB-AMB in the United States. A substance meeting the statutory requirements for temporary scheduling, 21 U.S.C. 811(h)(1), may only be placed in schedule I. Substances in Schedule I are those that have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. Available data and information for FUB-AMB indicate that this SC has a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. As required by section 201(h)(4) of the CSA, 21 U.S.C. 811(h)(4), the Administrator, through a letter dated May 19, 2017, notified the Assistant Secretary of the DEA's intention to temporarily place FUB-AMB in Schedule I. Conclusion This notice of intent initiates a temporary scheduling action and provides the 30-day notice pursuant to section 201(h) of the CSA, 21 U.S.C. 811(h), of the DEA's intent to issue a temporary scheduling order. In accordance with the provisions of section 201(h) of the CSA, 21 U.S.C. 811(h), the Administrator considered available data and information, herein sets forth the grounds for his determination that it is necessary to temporarily schedule methyl 2-(1-(4-fluorobenzyl)- 1H-indazole-3-carboxamido)-3-methylbutanoate [FUB-AMB, MMB-FUBINACA, AMB-FUBINACA] in Schedule I of the CSA, and finds that the placement of FUB-AMB into Schedule I of the CSA on a temporary basis is necessary to avoid an imminent hazard to the public safety. The temporary placement of FUB-AMB into Schedule I of the CSA will take effect pursuant to a temporary scheduling order, which will not be issued before October 11, 2017. Because the Administrator hereby finds that it is necessary to temporarily place FUB-AMB into Schedule I to avoid an imminent hazard to the public safety, the temporary order scheduling this substance will be effective on the date that order is published in the Federal Register, and will be in effect for a period of two years, with a possible extension of one additional year, pending completion of the regular (permanent) scheduling process. 21 U.S.C. 811(h)(1) and (2). It is the intention of the Administrator to issue a temporary scheduling order as soon as possible after the expiration of 30 days from the date of publication of this document. Upon publication of the temporary order, FUB-AMB will then be subject to the regulatory controls and administrative, civil, and criminal sanctions applicable to the manufacture, distribution, importation, exportation, research, conduct of instructional activities, and chemical analysis and possession of a Schedule I controlled substance. The CSA sets forth specific criteria for scheduling a drug or other substance. Regular scheduling actions in accordance with 21 U.S.C. 811(a) are subject to formal rulemaking procedures done ``on the record after opportunity for a hearing'' conducted pursuant to the provisions of 5 U.S.C. 556 and 557. 21 U.S.C. 811. The regular scheduling process of formal rulemaking affords interested parties with appropriate process and the government with any additional relevant information needed to make a determination. Final decisions that conclude the regular scheduling process of formal rulemaking are subject to judicial review. 21 U.S.C. 877. Temporary scheduling orders are not subject to judicial review. 21 U.S.C. 811(h)(6). Regulatory Matters Section 201(h) of the CSA, 21 U.S.C. 811(h), provides for an expedited temporary scheduling action where such action is necessary to avoid an imminent hazard to the public safety. As provided in this subsection, the Attorney General may, by order, schedule a substance in Schedule I on a temporary basis. Such an order may not be issued before the expiration of 30 days from (1) the publication of a notice in the Federal Register of the intention to issue such order and the grounds upon which such order is to be issued, and (2) the date that notice of the proposed temporary scheduling order is transmitted to the Assistant Secretary. 21 U.S.C. 811(h)(1). Inasmuch as section 201(h) of the CSA directs that temporary scheduling actions be issued by order and sets forth the procedures by which such orders are to be issued, the DEA believes that the notice and comment requirements of section 553 of the Administrative Procedure Act (APA), 5 U.S.C. 553, do not apply to this notice of intent. In the alternative, even assuming that this notice of intent might be subject to section 553 of the APA, the Administrator finds that there is good cause to forgo the notice and comment requirements of section 553, as any further delays in the process for issuance of temporary scheduling orders would be impracticable and contrary to the public interest in view of the manifest urgency to avoid an imminent hazard to the public safety. Although the DEA believes this notice of intent to issue a temporary scheduling order is not subject to the notice and comment requirements of section 553 of the APA, the DEA notes that in accordance with 21 U.S.C. 811(h)(4), the Administrator will take into consideration any comments submitted by the Assistant Secretary with regard to the proposed temporary scheduling order. Further, the DEA believes that this temporary scheduling action is not a ``rule'' as defined by 5 U.S.C. 601(2), and, accordingly, is not subject to the requirements of the Regulatory Flexibility Act (RFA). The requirements for the preparation of an initial regulatory flexibility analysis in 5 U.S.C. 603(a) are not applicable where, as here, the DEA is not required by section 553 of the APA or any other law to publish a general notice of proposed rulemaking. Additionally, this action is not a significant regulatory action as defined by Executive Order 12866 (Regulatory Planning and Review), section 3(f), and, accordingly, this action has not been reviewed by the Office of Management and Budget. This action will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, in accordance with Executive Order 13132 [[Page 42627]] (Federalism) it is determined that this action does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment. List of Subjects in 21 CFR Part 1308 Administrative practice and procedure, Drug traffic control, Reporting and recordkeeping requirements. For the reasons set out above, the DEA proposes to amend 21 CFR part 1308 as follows: PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES 0 1. The authority citation for part 1308 continues to read as follows: Authority: 21 U.S.C. 811, 812, 871(b), unless otherwise noted. 0 2. In Sec. 1308.11, add paragraph (h)(18) to read as follows: Sec. 1308.11 Schedule I. * * * * * (h) * * * (18) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3- (7021) methylbutanoate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: FUB-AMB, MMB-FUBINACA, AMB-FUBINACA).................................. Dated: August 14, 2017. Chuck Rosenberg, Acting Administrator. [FR Doc. 2017-17639 Filed 9-8-17; 8:45 am] BILLING CODE 4410-09-P
![42624 Federal Register / Vol. 82, No. 174 / Monday, September 11, 2017 / Proposed Rules
DEPARTMENT OF JUSTICE Legal Authority U.S.C. 355. The DEA has found that the
Section 201 of the Controlled control of FUB-AMB in Schedule I on a
Drug Enforcement Administration temporary basis is necessary to avoid
Substances Act (CSA), 21 U.S.C. 811,
provides the Attorney General with the imminent hazard to the public safety.
21 CFR Part 1308 To find that placing a substance
authority to temporarily place a
temporarily into Schedule I of the CSA
substance into Schedule I of the CSA for
[Docket No. DEA–472] is necessary to avoid an imminent
two years without regard to the
hazard to the public safety, the
requirements of 21 U.S.C. 811(b) if he Administrator is required to consider
Schedules of Controlled Substances:
finds that such action is necessary to three of the eight factors set forth in 21
Temporary Placement of FUB-AMB
avoid an imminent hazard to the public U.S.C. 811(c): The substance’s history
Into Schedule I
safety. 21 U.S.C. 811(h)(1). In addition, and current pattern of abuse; the scope,
AGENCY: Drug Enforcement if proceedings to control a substance are duration and significance of abuse; and
Administration, Department of Justice. initiated under 21 U.S.C. 811(a)(1), the what, if any, risk there is to the public
ACTION: Proposed amendment; notice of Attorney General may extend the health. 21 U.S.C. 811(h)(3).
intent. temporary scheduling for up to one Consideration of these factors includes
year. 21 U.S.C. 811(h)(2). actual abuse, diversion from legitimate
SUMMARY: The Administrator of the Drug Where the necessary findings are channels, and clandestine importation,
Enforcement Administration is issuing made, a substance may be temporarily manufacture, or distribution. 21 U.S.C.
this notice of intent to publish a scheduled if it is not listed in any other 811(h)(3).
temporary order to schedule the schedule under section 202 of the CSA, A substance meeting the statutory
synthetic cannabinoid, Methyl 2-(1-(4- 21 U.S.C. 812, or if there is no requirements for temporary scheduling
fluorobenzyl)-1H-indazole-3- exemption or approval in effect for the may only be placed in Schedule I. 21
carboxamido)-3-methylbutanoate [FUB- substance under section 505 of the U.S.C. 811(h)(1). Substances in
AMB, MMB-FUBINACA, AMB- Federal Food, Drug, and Cosmetic Act Schedule I are those that have a high
FUBINACA], into Schedule I. This (FDCA), 21 U.S.C. 355. 21 U.S.C. potential for abuse, no currently
action is based on a finding by the 811(h)(1); 21 CFR part 1308. The accepted medical use in treatment in the
Administrator that the placement of this Attorney General has delegated United States, and a lack of accepted
synthetic cannabinoid into Schedule I of scheduling authority under 21 U.S.C. safety for use under medical
the Controlled Substances Act is 811 to the Administrator of the DEA. 28 supervision. 21 U.S.C. 812(b)(1).
necessary to avoid an imminent hazard CFR 0.100.
to the public safety. When it is issued, FUB-AMB
Background
the temporary scheduling order will The illicit use of the synthetic
impose the administrative, civil, and Section 201(h)(4) of the CSA 21 U.S.C. cannabinoid (SC) methyl 2-(1-(4-
criminal sanctions and regulatory 811(h)(4), requires the Administrator to fluorobenzyl)-1H-indazole-3-
controls applicable to Schedule I notify the Secretary of the Department carboxamido)-3-methylbutanoate (Street
controlled substances under the of Health and Human Services (HHS) of names: FUB-AMB, MMB-FUBINACA,
Controlled Substances Act on the his intention to temporarily place a AMB-FUBINACA) has dramatically
manufacture, distribution, possession, substance into Schedule I of the CSA.2 increased over the past 12 months
importation, exportation of, and The Acting Administrator transmitted posing an imminent threat to public
research and conduct with, instructional notice of his intent to place FUB-AMB safety. Available data and information
activities of this synthetic cannabinoid. in Schedule I on a temporary basis to for FUB-AMB, summarized below,
DATES: September 11, 2017.
the Assistant Secretary for Health by indicates that this SC has a high
letter dated May 19, 2017. The Assistant potential for abuse, no currently
FOR FURTHER INFORMATION CONTACT:
Secretary responded to this notice of accepted medical use in treatment in the
Michael J. Lewis, Diversion Control intent by letter dated June 9, 2017, and United States, and a lack of accepted
Division, Drug Enforcement advised that based on a review by the safety for use under medical
Administration; Mailing Address: 8701 Food and Drug Administration (FDA), supervision. The DEA’s three factor
Morrissette Drive, Springfield, Virginia there were no approved new drug analysis is available in its entirety under
22152; Telephone: (202) 598–6812. applications or active investigational ‘‘Supporting and Related Material’’ of
SUPPLEMENTARY INFORMATION: This new drug applications for FUB-AMB. the public docket for this action at
notice of intent contained in this The Assistant Secretary also stated that www.regulations.gov under Docket
document is issued pursuant to the the HHS has no objection to the Number DEA–372.
temporary schedule provisions of 21 temporary placement of FUB-AMB into
U.S.C. 811(h). The Drug Enforcement Schedule I of the CSA. FUB-AMB is not Synthetic Cannabinoids
Administration (DEA) intends to issue a currently listed in any schedule under SCs are substances synthesized in
temporary scheduling order (in the form the CSA, and no exemptions or laboratories that mimic the biological
of a temporary amendment) to add FUB- approvals are in effect for FUB-AMB effects of delta-9-tetrahydrocannabinol
AMB to Schedule I under the Controlled under section 505 of the FDCA, 21 (THC), the main psychoactive ingredient
Substances Act.1 The temporary in marijuana. It is believed that SCs
asabaliauskas on DSKBBXCHB2PROD with PROPOSALS
scheduling order will be published in 2 As discussed in a memorandum of were first introduced on the designer
the Federal Register, but will not be understanding entered into by the Food and Drug drug market in several European
issued before October 11, 2017. Administration (FDA) and the National Institute on
Drug Abuse (NIDA), the FDA acts as the lead agency
countries as ‘‘herbal incense’’ before the
within the HHS in carrying out the Secretary’s initial encounter in the United States by
1 Though DEA has used the term ‘‘final order’’ scheduling responsibilities under the CSA, with the U.S. Customs and Border Protection
with respect to temporary scheduling orders in the concurrence of NIDA. 50 FR 9518, Mar. 8, 1985. (CBP) in November 2008. From 2009 to
past, this notice of intent adheres to the statutory The Secretary of the HHS has delegated to the
language of 21 U.S.C. 811(h), which refers to a Assistant Secretary for Health of the HHS the
the present, misuse and abuse of SCs
‘‘temporary scheduling order.’’ No substantive authority to make domestic drug scheduling has increased in the United States with
change is intended. recommendations. 58 FR 35460, July 1, 1993. law enforcement encounters describing
VerDate Sep<11>2014 16:09 Sep 08, 2017 Jkt 241001 PO 00000 Frm 00012 Fmt 4702 Sfmt 4702 E:\FR\FM\11SEP1.SGM 11SEP1](https://thefederalregister.org/doc/82_FR_42798/page/1.svg)
![42626 Federal Register / Vol. 82, No. 174 / Monday, September 11, 2017 / Proposed Rules
status, seizures, convulsions, loss of AMB, MMB-FUBINACA, AMB- not be issued before the expiration of 30
consciousness, and cardiotoxicity. By FUBINACA] in Schedule I of the CSA, days from (1) the publication of a notice
sharing pharmacological similarities and finds that the placement of FUB- in the Federal Register of the intention
with Schedule I substances (D9-THC, AMB into Schedule I of the CSA on a to issue such order and the grounds
JWH-018 and other temporarily and temporary basis is necessary to avoid an upon which such order is to be issued,
permanently controlled schedule I SCs), imminent hazard to the public safety. and (2) the date that notice of the
SCs pose a risk to the abuser. While The temporary placement of FUB- proposed temporary scheduling order is
these adverse effects have been shown AMB into Schedule I of the CSA will transmitted to the Assistant Secretary.
by a variety of SCs, similar concerns take effect pursuant to a temporary 21 U.S.C. 811(h)(1).
remain regarding the welfare of the user scheduling order, which will not be Inasmuch as section 201(h) of the
as it relates to abuse of products laced issued before October 11, 2017. Because CSA directs that temporary scheduling
with FUB-AMB. The risk of adverse the Administrator hereby finds that it is actions be issued by order and sets forth
health effects is further increased by the necessary to temporarily place FUB- the procedures by which such orders are
fact that similar products vary in the AMB into Schedule I to avoid an to be issued, the DEA believes that the
composition and concentration of SCs imminent hazard to the public safety, notice and comment requirements of
applied on the plant material. the temporary order scheduling this section 553 of the Administrative
substance will be effective on the date Procedure Act (APA), 5 U.S.C. 553, do
Finding of Necessity of Schedule I that order is published in the Federal not apply to this notice of intent. In the
Placement To Avoid Imminent Hazard Register, and will be in effect for a alternative, even assuming that this
to Public Safety period of two years, with a possible notice of intent might be subject to
In accordance with 21 U.S.C. extension of one additional year, section 553 of the APA, the
811(h)(3), based on the available data pending completion of the regular Administrator finds that there is good
and information summarized above, the (permanent) scheduling process. 21 cause to forgo the notice and comment
continued uncontrolled manufacture, U.S.C. 811(h)(1) and (2). It is the requirements of section 553, as any
distribution, importation, exportation, intention of the Administrator to issue further delays in the process for
conduct of research and chemical a temporary scheduling order as soon as issuance of temporary scheduling orders
analysis, possession, and abuse of FUB- possible after the expiration of 30 days would be impracticable and contrary to
AMB poses an imminent hazard to the from the date of publication of this the public interest in view of the
public safety. The DEA is not aware of document. Upon publication of the manifest urgency to avoid an imminent
any currently accepted medical uses for temporary order, FUB-AMB will then be hazard to the public safety.
FUB-AMB in the United States. A subject to the regulatory controls and Although the DEA believes this notice
substance meeting the statutory administrative, civil, and criminal of intent to issue a temporary
requirements for temporary scheduling, sanctions applicable to the manufacture, scheduling order is not subject to the
21 U.S.C. 811(h)(1), may only be placed distribution, importation, exportation, notice and comment requirements of
in schedule I. Substances in Schedule I research, conduct of instructional section 553 of the APA, the DEA notes
are those that have a high potential for activities, and chemical analysis and that in accordance with 21 U.S.C.
abuse, no currently accepted medical possession of a Schedule I controlled 811(h)(4), the Administrator will take
use in treatment in the United States, substance. into consideration any comments
and a lack of accepted safety for use The CSA sets forth specific criteria for submitted by the Assistant Secretary
under medical supervision. Available scheduling a drug or other substance. with regard to the proposed temporary
data and information for FUB-AMB Regular scheduling actions in scheduling order.
indicate that this SC has a high potential accordance with 21 U.S.C. 811(a) are Further, the DEA believes that this
for abuse, no currently accepted medical subject to formal rulemaking procedures temporary scheduling action is not a
use in treatment in the United States, done ‘‘on the record after opportunity ‘‘rule’’ as defined by 5 U.S.C. 601(2),
and a lack of accepted safety for use for a hearing’’ conducted pursuant to and, accordingly, is not subject to the
under medical supervision. As required the provisions of 5 U.S.C. 556 and 557. requirements of the Regulatory
by section 201(h)(4) of the CSA, 21 21 U.S.C. 811. The regular scheduling Flexibility Act (RFA). The requirements
U.S.C. 811(h)(4), the Administrator, process of formal rulemaking affords for the preparation of an initial
through a letter dated May 19, 2017, interested parties with appropriate regulatory flexibility analysis in 5 U.S.C.
notified the Assistant Secretary of the process and the government with any 603(a) are not applicable where, as here,
DEA’s intention to temporarily place additional relevant information needed the DEA is not required by section 553
FUB-AMB in Schedule I. to make a determination. Final of the APA or any other law to publish
decisions that conclude the regular a general notice of proposed
Conclusion
scheduling process of formal rulemaking.
This notice of intent initiates a rulemaking are subject to judicial Additionally, this action is not a
temporary scheduling action and review. 21 U.S.C. 877. Temporary significant regulatory action as defined
provides the 30-day notice pursuant to scheduling orders are not subject to by Executive Order 12866 (Regulatory
section 201(h) of the CSA, 21 U.S.C. judicial review. 21 U.S.C. 811(h)(6). Planning and Review), section 3(f), and,
811(h), of the DEA’s intent to issue a accordingly, this action has not been
temporary scheduling order. In Regulatory Matters reviewed by the Office of Management
asabaliauskas on DSKBBXCHB2PROD with PROPOSALS
accordance with the provisions of Section 201(h) of the CSA, 21 U.S.C. and Budget.
section 201(h) of the CSA, 21 U.S.C. 811(h), provides for an expedited This action will not have substantial
811(h), the Administrator considered temporary scheduling action where direct effects on the States, on the
available data and information, herein such action is necessary to avoid an relationship between the national
sets forth the grounds for his imminent hazard to the public safety. government and the States, or on the
determination that it is necessary to As provided in this subsection, the distribution of power and
temporarily schedule methyl 2-(1-(4- Attorney General may, by order, responsibilities among the various
fluorobenzyl)-1H-indazole-3- schedule a substance in Schedule I on levels of government. Therefore, in
carboxamido)-3-methylbutanoate [FUB- a temporary basis. Such an order may accordance with Executive Order 13132
VerDate Sep<11>2014 16:09 Sep 08, 2017 Jkt 241001 PO 00000 Frm 00014 Fmt 4702 Sfmt 4702 E:\FR\FM\11SEP1.SGM 11SEP1](https://thefederalregister.org/doc/82_FR_42798/page/3.svg)
![Federal Register / Vol. 82, No. 174 / Monday, September 11, 2017 / Proposed Rules 42627
(Federalism) it is determined that this submitted for parallel processing on July publicly available only at the hard copy
action does not have sufficient 12, 2017, by the State of Arkansas location (e.g., copyrighted material), and
federalism implications to warrant the through the Arkansas Department of some may not be publicly available at
preparation of a Federalism Assessment. Environmental Quality (ADEQ). either location (e.g., CBI).
Specifically, the EPA is proposing to FOR FURTHER INFORMATION CONTACT:
List of Subjects in 21 CFR Part 1308
approve the State’s proposed SIP Dayana Medina, 214–665–7241,
Administrative practice and revision, which addresses nitrogen medina.dayana@epa.gov. To inspect the
procedure, Drug traffic control, oxide (NOX) requirements for the hard copy materials, please schedule an
Reporting and recordkeeping Arkansas Electric Cooperative appointment with Dayana Medina or
requirements. Corporation (AECC) Bailey Plant Unit 1; Mr. Bill Deese at 214–665–7253.
For the reasons set out above, the DEA AECC McClellan Plant Unit 1; the SUPPLEMENTARY INFORMATION:
proposes to amend 21 CFR part 1308 as American Electric Power/Southwestern Throughout this document wherever
follows: Electric Power Company (AEP/ ‘‘we,’’ ‘‘us,’’ or ‘‘our’’ is used, we mean
SWEPCO) Flint Creek Plant Boiler No. the EPA.
PART 1308—SCHEDULES OF 1; Entergy Arkansas, Inc. (Entergy) Lake
CONTROLLED SUBSTANCES Catherine Plant Unit 4; Entergy White Table of Contents
Bluff Plant Units 1 and 2 and the I. Background
■ 1. The authority citation for part 1308 Auxiliary Boiler; and Entergy A. The Regional Haze Program
continues to read as follows: Independence Plant Units 1 and 2. In B. Our Previous Actions on Arkansas
Authority: 21 U.S.C. 811, 812, 871(b), conjunction with this proposed Regional Haze
unless otherwise noted. approval, we are proposing to withdraw C. CSAPR as an Alternative to Source-
Specific NOX BART
■ 2. In § 1308.11, add paragraph (h)(18) federal implementation plan (FIP) II. Our Evaluation of Arkansas’ Proposed
to read as follows: emission limits for NOX that would Regional Haze SIP Revision
otherwise apply to the nine A. Reliance on CSAPR To Satisfy NOX
§ 1308.11 Schedule I. aforementioned units. BART
* * * * * DATES: Written comments must be B. Reasonable Progress Analysis for NOX
(h) * * * received on or before October 11, 2017. 1. Regional Particulate Source
Apportionment Tool (PSAT) Data for
ADDRESSES: Submit your comments, Caney Creek and Upper Buffalo
(18) methyl 2-(1-(4-fluorobenzyl)- identified by Docket No. EPA–R06– 2. Arkansas Source PSAT Data for Caney
1H-indazole-3-carboxamido)-3- OAR–2015–0189, at http:// Creek and Upper Buffalo
methylbutanoate, its optical, 3. Arkansas’ Conclusions Regarding Key
www.regulations.gov or via email to
positional, and geometric iso- Pollutants and Source Category
mers, salts and salts of isomers R6AIR_ARHaze@epa.gov. Follow the
online instructions for submitting Contributions
(Other names: FUB-AMB, 4. Our Evaluation of Arkansas’ Analysis
MMB-FUBINACA, AMB- comments. Once submitted, comments C. Required Consultation
FUBINACA) ................................ (7021) cannot be edited or removed from III. Proposed Action
Regulations.gov. The EPA may publish A. Arkansas’ Proposed Regional Haze SIP
Dated: August 14, 2017. any comment received to its public Revision
Chuck Rosenberg, docket. Do not submit electronically any B. Partial FIP Withdrawal
Acting Administrator. information you consider to be C. Clean Air Act Section 110(l)
[FR Doc. 2017–17639 Filed 9–8–17; 8:45 am] Confidential Business Information (CBI) IV. Statutory and Executive Order Reviews
BILLING CODE 4410–09–P or other information whose disclosure is I. Background
restricted by statute. Multimedia
submissions (audio, video, etc.) must be A. The Regional Haze Program
ENVIRONMENTAL PROTECTION accompanied by a written comment. Regional haze is visibility impairment
AGENCY The written comment is considered the that is produced by a multitude of
official comment and should include sources and activities that are located
40 CFR Part 52 discussion of all points you wish to across a broad geographic area and emit
make. The EPA will generally not fine particulates (PM2.5) (e.g., sulfates,
[EPA–R06–OAR–2015–0189; FRL–9966–97– consider comments or comment nitrates, organic carbon (OC), elemental
Region 6] contents located outside of the primary carbon (EC), and soil dust), and their
Approval and Promulgation of submission (i.e. on the web, cloud, or precursors (e.g., sulfur dioxide (SO2),
Implementation Plans; Arkansas; other file sharing system). For NOX, and in some cases, ammonia (NH3)
Approval of Regional Haze State additional submission methods, please and volatile organic compounds
Implementation Plan Revision and contact Dayana Medina, (VOCs)). Fine particle precursors react
Withdrawal of Federal Implementation medina.dayana@epa.gov. For the full in the atmosphere to form PM2.5, which
Plan for NOX for Electric Generating EPA public comment policy, impairs visibility by scattering and
Units in Arkansas information about CBI or multimedia absorbing light. Visibility impairment
submissions, and general guidance on reduces the clarity, color, and visible
AGENCY: Environmental Protection making effective comments, please visit distance that can be seen. PM2.5 can also
asabaliauskas on DSKBBXCHB2PROD with PROPOSALS
Agency (EPA). http://www2.epa.gov/dockets/ cause serious adverse health effects and
ACTION: Proposed rule. commenting-epa-dockets. mortality in humans; it also contributes
Docket: The index to the docket for to environmental effects such as acid
SUMMARY: Pursuant to the Federal Clean this action is available electronically at deposition and eutrophication.
Air Act (CAA or the Act), the www.regulations.gov and in hard copy Section 169A of the CAA directs
Environmental Protection Agency (EPA) at the EPA Region 6, 1445 Ross Avenue, states to evaluate the use of retrofit
is proposing to approve a proposed Suite 700, Dallas, Texas. While all controls at certain larger, often under-
revision to the Arkansas Regional Haze documents in the docket are listed in controlled, older stationary sources in
State Implementation Plan (SIP) the index, some information may be order to address visibility impacts from
VerDate Sep<11>2014 16:09 Sep 08, 2017 Jkt 241001 PO 00000 Frm 00015 Fmt 4702 Sfmt 4702 E:\FR\FM\11SEP1.SGM 11SEP1](https://thefederalregister.org/doc/82_FR_42798/page/4.svg)
Document Created: 2017-09-09 00:03:54
Document Modified: 2017-09-09 00:03:54
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Proposed Rules | |
| Action | Proposed amendment; notice of intent. | |
| Dates | September 11, 2017. | |
| Contact | Michael J. Lewis, Diversion Control | |
| FR Citation | 82 FR 42624 | |
| CFR Associated | Administrative Practice and Procedure; Drug Traffic Control and Reporting and Recordkeeping Requirements |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR